Subtype
Lung Squamous Cell Carcinoma
CI-CAN-00003121LSCC · LUSCExplore in graph →
37 active trials14 evidence items
- NCIt
- C3493
- OncoTree
- LUSC
- DOID
- 3907
- UMLS CUI
- C0149782
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003121LSCC · LUSCExplore in graph →
Clinical trials
141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06436040 | Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | unknown | — | 40 | Tang-Du HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06207292 | Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer(STARTNEWERA-OM) | unknown | N/A | 100 | Radiotherapy Oncology Centre "Santa Maria" HospitalOTHER | 1 |
| Jan 16, 2024 |
| clinicaltrials |
| NCT05984017 | A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma | unknown | — | 130 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05782764 | A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | unknown | Phase 4 | 30 | Xuzhou Medical UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05395611 | Exhaled Breath Particles in Lung Cancer | unknown | — | 300 | Lund University HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05207904 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases | unknown | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05024266 | Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma(TACT) | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT05010330 | Identify Prognostic Biomarkers of Lung Cancer | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT04846452 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03823625 | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)(SQUINT) | unknown | Phase 2 | 112 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04306042 | A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy | unknown | — | 1,000 | Guangdong Association of Clinical TrialsOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04132102 | To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation | unknown | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT03938012 | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma | unknown | — | 80 | National University Hospital, SingaporeOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03725423 | Apatinib for Advanced Lung Squmamous Carcinoma | unknown | Phase 4 | 50 | Xuzhou Central HospitalOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT02852083 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC(ModuLung) | unknown | Phase 2 | 86 | University Hospital RegensburgOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | unknown | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02787473 | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer | unknown | Phase 2 | 54 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02876978 | Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | unknown | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT01801852 | Autologous Natural Killer T Cells Infusion for the Treatment of Cancer | unknown | N/A | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01660399 | Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy | unknown | Phase 2 | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT02009605 | Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer | unknown | Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02288026 | Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer | unknown | — | 630 | Capital Medical UniversityOTHER | 1 | Nov 11, 2014 | clinicaltrials |
| NCT01969955 | Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer | unknown | Phase 2 | 50 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 25, 2014 | clinicaltrials |
| NCT01947062 | Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma | unknown | Phase 3 | 60 | Swami Rama Cancer Hospital and Research InstituteINDUSTRY | 1 | Sep 20, 2013 | clinicaltrials |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours(FGFR) | unknown | Phase 2 | 48 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2013 | clinicaltrials |
Data updated 22 days agoSource updated May 30, 2024source: clinicaltrials